{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:18Z","timestamp":1792479138144,"version":"4.5.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Transthyretin related cardiac amyloidosis (TTR-CA) is an infiltrative cardiomyopathy that cause heart failure with preserved ejection fraction, mainly in aging people. Due to the introduction of a non invasive diagnostic algorithm, this disease, previously considered to be rare, is increasingly recognized. The natural history of TTR-CA includes two different stages: a presymptomatic and a symptomatic stage. Due to the availability of new disease-modifying therapies, the need to reach a diagnosis in the first stage has become impelling. While in variant TTR-CA an early identification of the disease may be obtained with a genetic screening in proband's relatives, in the wild-type form it represents a challenging issue. Once the diagnosis has been made, in order to identifying patients with a higher risk of cardiovascular events and death it is necessary to focus on risk stratification. Two prognostic scores have been proposed both based on biomarkers and laboratory findings. However, a multiparametric approach combining information from electrocardiogram, echocardiogram, cardiopulmonary exercise test and cardiac magnetic resonance may be warranted for a more comprehensive risk prediction. In this review, we aim at evaluating a step by step risk stratification, providing a clinical diagnostic and prognostic approach for the management of patients with TTR-CA.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1151803","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:04:34Z","timestamp":1679461474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk stratification in transthyretin-related cardiac amyloidosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Riccardo","family":"Scirpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cittadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Tini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domitilla","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Imperatrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Autore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.20517\/2574-1209.2021.74","article-title":"Clinical translation of genetic testing in TTR amyloidosis: genotype-phenotype correlations, management of asymptomatic carriers and familial screening","volume":"6","author":"Scirpa","year":"2022","journal-title":"Vessel Plus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","article-title":"Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS","volume":"10","author":"Gentile","year":"2021","journal-title":"Cardiol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"key":"B16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus","volume":"15","author":"Grandis","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","article-title":"Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?","volume":"108","author":"Aus dem Siepen","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacc.2019.04.054","article-title":"Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes","volume":"74","author":"Fosb\u00f8l","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5\u201315 years after surgery for bilateral carpal tunnel syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study","volume":"329","author":"Vianello","year":"2021","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ehf2.14173","article-title":"Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS) [published online ahead of print, 2022 Oct 3]","volume":"10","author":"Ladefoged","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiacamyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13449","DOI":"10.1111\/eci.13449","article-title":"A simple echocardiographic score to rule out cardiac amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaccao.2021.05.007","article-title":"Cardiac transplantation and mechanical circulatory support in amyloidosis","volume":"3","author":"Witteles","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system [published correction appears in J Am Coll Cardiol. 2017 Jun 13;69(23):2882]","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can J Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC Cardio Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00392-019-01559-y","article-title":"A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis","volume":"109","author":"Kreusser","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","article-title":"Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value","volume":"4","author":"Cipriani","year":"2022","journal-title":"JACC Cardio Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cardfail.2018.07.001","article-title":"Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis","volume":"24","author":"Rubin","year":"2018","journal-title":"J Card Fail"},{"key":"B44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"B45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13506129.2016.1194264","article-title":"Prognostic value of right ventricular systolic function in cardiac amyloidosis","volume":"23","author":"Bodez","year":"2016","journal-title":"Amyloid"},{"key":"B46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2022.02.048","article-title":"Prognostic implications of right ventricular systolic dysfunction in cardiac amyloidosis","volume":"173","author":"Tjahjadi","year":"2022","journal-title":"Am J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14;:]","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"898033","DOI":"10.3389\/fcvm.2022.898033","article-title":"Diagnostic and prognostic values of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"9","author":"Banydeen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ejhf.2016","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13506129.2018.1496077","article-title":"Peak VO2 is an independent predictor of survival in patients with cardiac amyloidosis","volume":"25","author":"Hein","year":"2018","journal-title":"Amyloid"},{"key":"B52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.amjcard.2019.03.035","article-title":"Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis","volume":"124","author":"Yunis","year":"2019","journal-title":"Am J Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: cardioOncology state-of-the-art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.amjcard.2020.12.024","article-title":"Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis","volume":"143","author":"Thakkar","year":"2021","journal-title":"Am J Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologiccorrelation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemicembolism in amyloidtransthyretincardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.jacc.2019.02.078","article-title":"Predicting the unpredictable: how to score the risk of stroke in cardiac amyloidosis?","volume":"73","author":"Russo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jce.14541","article-title":"Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: a systematic review and meta-anaylsis","volume":"31","author":"Halawa","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e016038","DOI":"10.1161\/JAHA.120.016038","article-title":"Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy","volume":"9","author":"Higgins","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3390\/jcm10091858","article-title":"Arrhythmic sudden cardiac death and the role of implantable cardioverter-defibrillator in patients with cardiac amyloidosis-a narrative literature review","volume":"10","author":"Li\u017cewska-Springer","year":"2021","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1073503","DOI":"10.3389\/fcvm.2022.1073503","article-title":"Changing paradigm in the treatment of amyloidosis: from disease-modifying drugs to anti-fibril therapy","volume":"9","author":"Quarta","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1151803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:04:37Z","timestamp":1679461477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1151803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":82,"alternative-id":["10.3389\/fcvm.2023.1151803"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1151803","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"article-number":"1151803"}}